Bristol-Myers Squibb Company
OXABICYCLO ACIDS AS LPA ANTAGONISTS
Last updated:
Abstract:
The present invention provides compounds of Formula (Ia) or (Ib) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors. ##STR00001##
Status:
Application
Type:
Utility
Filling date:
16 Sep 2019
Issue date:
14 Oct 2021